(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Acurx Pharmaceuticals's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ACXP's revenue for 2025 to be $0, with the lowest ACXP revenue forecast at $0, and the highest ACXP revenue forecast at $0. On average, 3 Wall Street analysts forecast ACXP's revenue for 2030 to be $139,274,781, with the lowest ACXP revenue forecast at $133,813,647, and the highest ACXP revenue forecast at $143,371,425.
In 2031, ACXP is forecast to generate $181,773,693 in revenue, with the lowest revenue forecast at $174,642,205 and the highest revenue forecast at $187,114,384.